A 32-year-old male is experiencing hair loss despite using 0.5 mg Dutasteride and 2.5 mg Minoxidil daily, along with previous hair transplants and Finasteride use. He is considering increasing Dutasteride dosage and exploring other treatments like RU58841, but remains skeptical about their effectiveness and concerned about costs.
The user reports losing a significant amount of hair when applying RU58841 and Minoxidil but loses much less hair when massaging or brushing without these treatments. They are concerned about the increased hair loss associated with these products.
The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
A user stopped using finasteride and topical minoxidil for 2 years, saw hair thinning, then restarted the treatments along with weekly dermastamping and regained their previous hair status. The user suggests that restarting treatment can be effective even after a break.
PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.
Body hair transplants may look better if kept very short. People with limited donor regions or waiting for Verteporfin or FAK Inhibitors could consider this option.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
The user experienced hair loss due to a crash diet and later developed scarring hair loss. They are now on finasteride, oral minoxidil, LDN, Zyrtec, and Oztela to reduce scalp inflammation and promote hair regrowth.
A user discussed their hair transplant progress and mentioned using 1mg Finasteride, 5% Topical Minoxidil, and recently starting 5% RU58841. They are seeking advice on whether to use RU58841 at month 4 post-transplant.
This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.
Botox is found to be as effective as finasteride in treating hair loss. Users discuss combining treatments like botox, minoxidil, and massages for better results.
Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.
Using finasteride before a hair transplant can prevent further hair loss and make the transplant look more natural. Patients should continue using finasteride until hair cloning becomes available.
The conversation discusses using RU58841 for hair loss, with OP experiencing thinning in the front area and steady hair loss. OP plans to try microneedling while avoiding finasteride and dutasteride.
Microneedling at depths greater than 0.6 mm may damage miniaturized hair follicles, with 0.5 mm showing better results for hair regrowth. Combining microneedling with minoxidil enhances absorption, but caution is advised to avoid damaging follicles.
PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.
The conclusion of the conversation is that the user, PirateBeastBaby, had good results with microneedling for hair loss after using oral finasteride and topical minoxidil 20 years ago. They believe that microneedling was the gamechanger for their hair growth.
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
Bhringraj oil showed better hair regrowth results than minoxidil in mice, but its effectiveness in humans is uncertain. Users discussed using bhringraj oil, coconut oil, and microneedling for hair regrowth, with some reporting slow but noticeable improvements.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.